Beiya3D
Develops and manufactures personalized 3D-printed regenerative implants and digital medical models for orthopedic, cranial, and reconstructive surgery.
- CEO / Founder
- 樊渝江
- Team Size
- 11-50
- Stage
- Growth Stage
- Total Funding
- $4.2M
- Latest Round
- Series A+
- Key Investors
- Huaxi Securities (via Huaxi Yinfeng Investment)
Technology & Products
Key Products
Personalized bone-regeneration repair implants; Custom 3D-printed anatomical models; Personalized orthopedic surgical guides; Surgery and radiotherapy assistive devices; Rehabilitation braces/orthoses
Technological Advantage
Proprietary DLP-based bioprinting process for creating patient-specific, osteoinductive bioceramic scaffolds, protected by patents (e.g., US12011515B2, CN105877874B). Core IP is defensible via a patent portfolio focused on avoiding stress shielding and promoting bone ingrowth. Process advantage is replicable by well-funded competitors, but material formulation and regulatory expertise create a barrier.
Differentiation
Value Proposition
Provides a complete digital medical service platform and personalized implant solutions, reducing surgical planning time and improving patient-specific anatomical fit and regenerative outcomes.
How They Differentiate
Focus on osteoinductive, patient-specific bioceramic implants using DLP printing, compared to generic PBF-LB metal implants from larger players. Integrates digital platform for end-to-end surgical planning.
Market & Competition
Target Customers
Hospitals, medical institutions, and individual patients
Industry Verticals
Medical Devices; Healthcare
Competitors
No direct competitors in the same AM segment (personalized 3D-printed regenerative implants via bioprinting) identified from provided sources.
Growth & Milestones
Growth Metrics
No specific growth metrics (revenue, customer count, facility expansion) found in provided sources.
Major Milestones
Founded in 2019; Achieved National High-Tech Enterprise status; Established ISO 13485 certified quality management system; Built ~400 sqm Class 10,000 cleanroom production facility; Secured Series A+ funding in September 2025
Notable Customers
No verifiable specific customer names found in provided sources; company website states collaboration with domestic and international medical institutions across orthopedics, neurosurgery, oncology, spine, respiratory, rehabilitation, and medical aesthetics.